87 related articles for article (PubMed ID: 34988768)
21. Health insurance coverage and cost barriers to needed medical care among U.S. adult cancer survivors age<65 years.
Sabatino SA; Coates RJ; Uhler RJ; Alley LG; Pollack LA
Cancer; 2006 Jun; 106(11):2466-75. PubMed ID: 16639732
[TBL] [Abstract][Full Text] [Related]
22. Health insurance and other factors associated with mammography surveillance among breast cancer survivors: results from a national survey.
Sabatino SA; Thompson TD; Richardson LC; Miller J
Med Care; 2012 Mar; 50(3):270-6. PubMed ID: 22193416
[TBL] [Abstract][Full Text] [Related]
23. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
[TBL] [Abstract][Full Text] [Related]
24. Cost-Related Medication Nonadherence in Adults With Diabetes in the United States: The National Health Interview Survey 2013-2018.
Taha MB; Valero-Elizondo J; Yahya T; Caraballo C; Khera R; Patel KV; Ali HJR; Sharma G; Mossialos E; Cainzos-Achirica M; Nasir K
Diabetes Care; 2022 Mar; 45(3):594-603. PubMed ID: 35015860
[TBL] [Abstract][Full Text] [Related]
25. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
26. Health Insurance Coverage Disruptions and Access to Care and Affordability among Cancer Survivors in the United States.
Zhao J; Han X; Nogueira L; Zheng Z; Jemal A; Yabroff KR
Cancer Epidemiol Biomarkers Prev; 2020 Nov; 29(11):2134-2140. PubMed ID: 32868319
[TBL] [Abstract][Full Text] [Related]
27. Socioeconomic and Demographic Characteristics of US Adults Who Purchase Prescription Drugs From Other Countries.
Hong YR; Hincapie-Castillo JM; Xie Z; Segal R; Mainous AG
JAMA Netw Open; 2020 Jun; 3(6):e208968. PubMed ID: 32579194
[TBL] [Abstract][Full Text] [Related]
28. Recent trends in cost-related medication nonadherence among stroke survivors in the United States.
Levine DA; Morgenstern LB; Langa KM; Piette JD; Rogers MA; Karve SJ
Ann Neurol; 2013 Feb; 73(2):180-8. PubMed ID: 23436312
[TBL] [Abstract][Full Text] [Related]
29. Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events.
Hershman DL; Accordino MK; Shen S; Buono D; Crew KD; Kalinsky K; Trivedi MS; Hur C; Hu J; Unger JM; Wright JD
Cancer; 2020 Apr; 126(7):1541-1549. PubMed ID: 31913500
[TBL] [Abstract][Full Text] [Related]
30. Cost-related medication nonadherence among over-indebted individuals enrolled in statutory health insurance in Germany: a cross-sectional population study.
Warth J; Puth MT; Tillmann J; Beckmann N; Porz J; Zier U; Weckbecker K; Weltermann B; Münster E
BMC Health Serv Res; 2019 Nov; 19(1):887. PubMed ID: 31771583
[TBL] [Abstract][Full Text] [Related]
31. Impact of the Patient Protection and Affordable Care Act on cost-related medication underuse in nonelderly adult cancer survivors.
Barnes JM; Johnson KJ; Adjei Boakye E; Sethi RKV; Varvares MA; Osazuwa-Peters N
Cancer; 2020 Jun; 126(12):2892-2899. PubMed ID: 32187662
[TBL] [Abstract][Full Text] [Related]
32. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
[TBL] [Abstract][Full Text] [Related]
33. Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors.
Wheeler SB; Kohler RE; Reeder-Hayes KE; Goyal RK; Lich KH; Moore A; Smith TW; Melvin CL; Muss HB
J Cancer Surviv; 2014 Dec; 8(4):603-10. PubMed ID: 24866922
[TBL] [Abstract][Full Text] [Related]
34. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
[TBL] [Abstract][Full Text] [Related]
35. Gender differences in cost-related medication non-adherence among cancer survivors.
Lee M; Khan MM
J Cancer Surviv; 2016 Apr; 10(2):384-93. PubMed ID: 26350680
[TBL] [Abstract][Full Text] [Related]
36. Sleep medication use and risk of fractures in breast cancer survivors.
Haque R; Chlebowski RT; Chen L
Breast Cancer Res Treat; 2021 Dec; 190(3):541-548. PubMed ID: 34586512
[TBL] [Abstract][Full Text] [Related]
37. Economic outcomes of breast cancer survivorship: CALGB study 79804.
Hensley ML; Dowell J; Herndon JE; Winer E; Stark N; Weeks JC; Paskett E
Breast Cancer Res Treat; 2005 May; 91(2):153-61. PubMed ID: 15868443
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
Ito K; Elkin E; Blinder V; Keating N; Choudhry N
Cancer; 2013 Jul; 119(13):2494-502. PubMed ID: 23775433
[TBL] [Abstract][Full Text] [Related]
39. Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.
Neugut AI; Zhong X; Wright JD; Accordino M; Yang J; Hershman DL
JAMA Oncol; 2016 Oct; 2(10):1326-1332. PubMed ID: 27281650
[TBL] [Abstract][Full Text] [Related]
40. Long-term decision regret surrounding systemic therapy in older breast cancer survivors: A population-based survey study.
Karuturi MS; Lei X; Shen Y; Giordano SH; Swanick CW; Smith BD
J Geriatr Oncol; 2019 Nov; 10(6):973-979. PubMed ID: 30940493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
